Association of the epithelial-to-mesenchymal transition phenotype with responsiveness to the p21-activated kinase inhibitor, PF-3758309, in colon cancer models
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
The p21-activated kinase (PAK) family of serine/threonine kinases, which are overexpressed in several cancer types, are critical mediators of cell survival, motility, mitosis, transcription, and translation. In the study presented here, we utilized a panel of colorectal cancer (CRC) cell lines to identify potential biomarkers of sensitivity or resistance that may be used to individualize therapy to the PAK inhibitor PF-03758309. We observed a wide range of proliferative responses in the CRC cell lines exposed to PF-03758309, this response was recapitulated in other phenotypic assays such as anchorage-independent growth, three-dimensional (3D) tumor spheroid formation, and migration. Interestingly, we observed that cells most sensitive to PF-03758309 exhibited up-regulation of genes associated with a mesenchymal phenotype (CALD1, VIM, ZEB1) and cells more resistant had an up-regulation of genes associated with an epithelial phenotype (CLDN2, CDH1, CLDN3, CDH17) allowing us to derive an epithelial-to-mesenchymal transition (EMT) gene signature for this agent. We assessed the functional role of EMT-associated genes in mediating responsiveness to PF-3758309, by targeting known genes and transcriptional regulators of EMT. We observed that suppression of genes associated with the mesenchymal phenotype conferred resistance to PF-3758309, in vitro and in vivo. These results indicate that PAK inhibition is associated with a unique response phenotype in CRC and that further studies should be conducted to facilitate both patient selection and rational combination strategies with these agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yauch, R. L., Januario, T., Eberhard, D. A., Cavet, G., Zhu, W., Fu, L., Pham, T. Q., Soriano, R., Stinson, J., Seshagiri, S., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1492 · Cited by 495
Cited by
Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer
Vaishnavi, A., Capelletti, M., Le, A. T., Kako, S., Butaney, M., Ercan, D., Mahale, S., Davies, K. D., Aisner, D. L., Pilling, A. B., et al. (2013) · Nature Medicine · doi:10.1038/nm.3352 · Cited by 607
Self-citationPAK signalling during the development and progression of cancer
Radu, M., Semenova, G., Kosoff, R., & Chernoff, J. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3645 · Cited by 503
van Staalduinen, J., Baker, D., ten Dijke, P., & van Dam, H. (2018) · Oncogene · doi:10.1038/s41388-018-0378-x · Cited by 158
Ma, W., Wang, Y., Zhang, R., Yang, F., Zhang, D., Huang, M., Zhang, L., Dorsey, J. F., Binder, Z. A., O’Rourke, D. M., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-00147-8 · Cited by 143
Pitts, T. M., Newton, T. P., Bradshaw-Pierce, E. L., Addison, R., Arcaroli, J. J., Klauck, P. J., Bagby, S. M., Hyatt, S. L., Purkey, A., Tentler, J. J., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0113037 · Cited by 54
“Sulforhodamine B assay (SRB) was performed as described previously [30].”
MethodSelf-citation
Metadata
- Authors
- Pitts, T. M., Kulikowski, G. N., Tan, A.-C., Murray, B. W., Arcaroli, J. J., Tentler, J. J., Spreafico, A., Selby, H. M., Kachaeva, M. I., McPhillips, K. L., Britt, B. C., Bradshaw-Pierce, E. L., Messersmith, W. A., Varella-Garcia, M., & Eckhardt, S. G.
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2013
- Volume
- 4
- Pages
- 35-35
- ISSN
- 1663-9812 (ISSN-L)
- OpenAlex
- W2110014936
- Cited by
- 38
- References
- 1
- FWCI
- 2.37
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Association of the epithelial-to-mesenchymal transition phenotype with responsiveness to the p21-activated kinase inhibitor, PF-3758309, in colon cancer models. https://app.cochat.ai/papers/10.3389/fphar.2013.00035
- The paper
- Pitts, T. M., Kulikowski, G. N., Tan, A.-C., Murray, B. W., Arcaroli, J. J., Tentler, J. J., Spreafico, A., Selby, H. M., Kachaeva, M. I., McPhillips, K. L., Britt, B. C., Bradshaw-Pierce, E. L., Messersmith, W. A., Varella-Garcia, M., & Eckhardt, S. G. (2013). Association of the epithelial-to-mesenchymal transition phenotype with responsiveness to the p21-activated kinase inhibitor, PF-3758309, in colon cancer models. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2013.00035
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.